Rapamycin and Longevity: A Groundbreaking Clinical Trial in Healthy People

In March 2026, UT Health San Antonio, one of the leading medical research institutions in the United States, announced the launch of a new clinical trial: testing the effect of rapamycin on healthy aging in people. This announcement, which did not make mainstream headlines, is a significant moment for the field of geroscience, the study of aging as a biological phenomenon that can be slowed.

The story of rapamycin is one of the most surprising in modern medicine. A drug derived from a soil sample from Easter Island, currently used to prevent organ transplant rejection, has become the holy grail of longevity researchers. In every living model tested: yeast, worms, flies, mice, it succeeded in extending lifespan. The question that has remained open for 20 years is: will it work in humans as well? The new UT Health San Antonio trial is expected to provide an initial answer.

What is Rapamycin?

Rapamycin, also known as sirolimus, is a molecule with an extraordinary history:

• Origin: The soil from which it was isolated was collected in 1964 during a medical expedition to Easter Island (Rapa Nui), and the drug itself was isolated and named around 1975, hence the name. It is produced by a bacterium called Streptomyces hygroscopicus.
• Current clinical use: Approved by the FDA to prevent kidney transplant rejection and to treat certain rare diseases.
• Mechanism: It inhibits a protein called mTOR (mechanistic Target Of Rapamycin), a central switch that regulates cell growth, protein production, and metabolism.
• Unique property: While many drugs extend lifespan in mice only when started from birth, rapamycin also works when started at an older age.

The transition from an anti-rejection drug to a potential longevity drug is one of the most fascinating stories of drug repurposing, finding new uses for existing drugs.

The Connection to Longevity: The mTOR Mechanism and Autophagy

To understand why rapamycin can slow aging, one needs to understand mTOR. This protein acts like a central 'growth switch' in the cell:

• When food is available, mTOR is active and instructs the cell to grow, divide, and produce proteins.
• When food is absent (fasting, caloric restriction), mTOR is deactivated. The cell then shifts to a 'maintenance' mode: it breaks down damaged proteins, cleans up malfunctioning organelles, and conserves energy.

This process of cleaning and maintenance is called autophagy, literally 'self-eating'. Cells that undergo autophagy regularly remain younger, accumulate less damage, and function better. Aging, at the cellular level, is largely a failure of autophagy.

Rapamycin mimics the effect of fasting: it inhibits mTOR even when food is present, causing the cell to activate autophagy. Additionally, it affects:

• Senescent cells (zombie cells): Rapamycin reduces the accumulation of aging cells that emit inflammatory signals.
• Immune system: At low doses, it rejuvenates the immune response in the elderly, a surprising finding reported in studies by Novartis and the company that spun off from it, resTORbio (led by Dr. Joan Mannick).
• Mitochondrial function: It affects mitochondrial biogenesis, the creation of new energy organelles.
• Chronic inflammation: It can lower inflammatory markers like IL-6 and TNF-alpha, which increase with age.

Current Evidence

Study 1: ITP Mouse Study, the Landmark Discovery from 2009

The experiment that made rapamycin a star was the Interventions Testing Program (ITP), an NIH project that tested various drugs in genetically diverse mice. The findings were published in Nature (Harrison et al., 2009). In the extended study, rapamycin extended the lifespan of male mice by 9% and females by 14% (measured at the age of 90% mortality), even when treatment was started at 600 days of age, roughly equivalent to age 60 in humans. This was the first study to show that lifespan could be extended in older mice with a drug.

Study 2: Mannick et al. on the Immune System in the Elderly (2014, 2018)

Researchers working at Novartis (who later founded resTORbio) tested mTOR inhibition in the elderly. In the 2014 study, administering a rapamycin analog (RAD001) at a low dose before a flu vaccine improved the immune response to the vaccine by about 20%. In the follow-up study from 2018 (Mannick et al., Science Translational Medicine), 264 elderly individuals received a low-dose combination of mTOR inhibitors (RAD001 and BEZ235), and a statistically significant reduction in the rate of reported infections over one year was observed (P=0.001): the treatment group reported fewer infections than the placebo group. In a later follow-up trial with RTB101, a reduction of about 30.6% was reported in the rate of participants experiencing one or more laboratory-confirmed respiratory infections. These were the first clinical proofs that mTOR inhibition could support immune function in humans.

Study 3: PEARL Trial, a Trial in Healthy People (2020-2024)

A private project called Participatory Evaluation of Aging With Rapamycin for Longevity (PEARL), one of the largest trials of rapamycin in healthy people. 114 participants aged 50-85 received a placebo, or 5mg, or 10mg of weekly rapamycin for about a year (48 weeks), in a randomized, double-blind design. The study did not meet its primary endpoint (reduction of visceral fat), but the most notable finding was a significant increase of about 5% in lean mass among women who received the 10mg dose, along with a reduction in reported pain. This was a sex-dependent and dose-dependent effect, not a general improvement. However, the study was relatively small.

Study 4: Large Dogs, the Dog Aging Project (TRIAD)

The TRIAD (Test of Rapamycin in Aging Dogs) trial of the Dog Aging Project, a multi-center effort led by Texas A&M University (in collaboration with the University of Washington and other institutions), is testing rapamycin in large, older dogs. The goal is to enroll about 580 dogs across 20 centers; as of the latest reports, about 170 dogs have been enrolled. An earlier trial in healthy middle-aged dogs showed trends towards improved cardiac function (systolic and diastolic) after about 10 weeks of low-dose treatment, but these were trends and not a definitive final result. Large dogs age quickly and die from the same age-related diseases as humans, making this model particularly relevant.

The New UT Health San Antonio Trial (2026)

The trial announced on March 25, 2026, is a multi-phase academic study funded by the National Institute on Aging (NIA) that examines how to use rapamycin to promote healthy aging. The largest sub-study includes about 84 participants. The protocol includes:

• Drugs: Two FDA-approved mTOR inhibitor drugs, rapamycin and everolimus.
• Dosing arms: Daily dose, vs. intermittent dose, vs. placebo.
• Duration: A treatment phase of about 6 weeks followed by a follow-up period of about 4 weeks in the current recruitment phase.
• Population: Healthy adults aged 65-90, non-smokers, living independently, without diabetes.
• Primary endpoints: Biomarkers and immune markers, safety and dosing, as a basis for follow-up studies on healthspan.
• Funding: An NIA grant, with no commercial pharmaceutical company involvement.

The researchers leading the study are Ellen Kraig, Dean Kellogg Jr., and Brett Ginsburg.

Why Rapamycin Became the Holy Grail

In the longevity field, there are dozens of candidates: metformin, NMN, NR, spermidine, fisetin, quercetin. So why did rapamycin achieve a special status? Three main reasons:

1. Exceptional consistency in models: While other supplements have shown conflicting results between labs, rapamycin has shown lifespan extension across a variety of labs and mouse strains tested. This hinted at a real mechanism, not a methodological flaw.
2. Clear mechanism of action: Most supplements sold in the industry lack a well-defined mechanism, or the mechanism is still debated. mTOR, on the other hand, is one of the most well-documented pathways in biology.
3. Effect even at an older age: Most anti-aging supplements work only if started in youth. Rapamycin has shown an effect even when started at an older age, making it practically relevant.

Additionally, rapamycin has a practical advantage: it is a generic drug, relatively cheap and accessible. At a cost of about $100-300 per month, it is within reach for those willing to get an off-label prescription.

The Dark Side: Side Effects and Risks

Rapamycin is not without risks. At high doses, as given to organ transplant recipients, it causes:

• Immunosuppression, with an increased risk of respiratory and urinary tract infections.
• Metabolic disturbances, increased blood lipids and increased blood sugar levels.
• Mouth sores (stomatitis) in about 10-30% of patients (mainly at high doses).
• Lung function disorders, a low but documented risk of pneumonitis.
• Impaired wound healing, important before surgeries.

The reason longevity researchers believe healthy humans can benefit without harm is low, cyclic dosing. Instead of a high daily dose, a single weekly dose is given. This is intended to activate autophagy strongly enough to create an anti-aging effect, but without suppressing the immune system over time.

However, this assumption has not yet been proven on a large scale. The UT Health San Antonio trial is precisely the attempt to verify it.

The Gap Between Mice and Humans

An important caveat: mice are not small humans. The great success of rapamycin in mice does not guarantee success in humans, for many reasons:

• Lab mice live in a sterile environment, eat a uniform diet, and are not exposed to routine infections. In humans, mild immunosuppression could be more problematic.
• Different metabolic systems: mice rely more on fat oxidation, humans more on glucose.
• Different lifespan: a 14% extension in a mouse (living two years) equals 3-4 months. A 14% extension in a human (living 80 years) equals 11 years. There is no guarantee the effect is linear.
• Response time: a study in humans would require many years to show an effect on lifespan, so researchers rely on biological age markers, epigenetic markers, inflammatory markers, physical function.

The 'Biohacker' Community Ahead of the Science

While academia moves slowly, a large community of people has been taking rapamycin off-label for several years. In podcasts by Peter Attia and David Sinclair, the prevailing opinion is that taking a low weekly dose of rapamycin may be safe and potentially beneficial for middle-aged and older humans.

Companies named AgelessRx and Healthspan offer off-label prescriptions for rapamycin via telemedicine, with monitoring of blood markers. But this is still an uncontrolled experiment on many people. Without systematic data, there is no way to know if there is a real effect, what the real risk is, and who truly benefits.

Should You Take Rapamycin?

The short answer: Not until there are more results from controlled trials like the one at UT Health. The reasons:

If you are a healthy person under 50

The potential risk, mild immunosuppression, effects on metabolism, outweighs the expected benefit. Your body is already functioning well.

If you are over 65 with health problems

Here the decision is complex. The benefit may be large enough to justify a trial, but only under the supervision of a doctor familiar with the treatment and able to monitor it.

If you have an autoimmune disease

This might actually be a legitimate use. Rapamycin is an immunosuppressant, and there are promising studies on its use in autoimmune diseases. But not as an anti-aging drug, rather as a specific disease treatment.

If you are a candidate for participation in the clinical trial

This is the best way to be exposed to rapamycin: in a controlled environment, with close medical monitoring, and contributing to science. UT Health San Antonio is recruiting participants aged 65-90. It is recommended to check their website.

What to Do Now

1. Activate autophagy naturally. Fasting for 14-16 hours a day, or longer fasts occasionally, activates pathways that overlap with those rapamycin activates. No side effects, no cost, and reasonable evidence.
2. Moderately restrict calories. Moderate restriction of usual calorie intake affects AMPK pathways and suppresses mTOR naturally.
3. Intense physical activity. HIIT training, resistance training, and regular aerobic activity mimic some of the metabolic effects of mTOR inhibition.
4. Quality sleep. During deep sleep, the body activates autophagy and repair mechanisms. Poor sleep negates much of the benefit of any longevity drug.
5. Follow the trial results. As results from the UT Health Trial and other studies are published, the picture will become clearer. If a significant effect on biological age is seen, the market will move quickly. If significant side effects are seen, the movement will slow down.

The Broader Perspective

The UT Health San Antonio trial is more than just a study on a drug. It is a milestone for the geroscience agenda: the field that argues that aging itself is a process that can be treated, not just a sequence of unrelated diseases. If the trial shows positive results, it will change how regulators, doctors, and insurance companies think about aging.

It is important to remember: no single drug will solve aging. Aging is a system of interconnected biological processes, what researchers call The Hallmarks of Aging. Rapamycin addresses some of them, but not all. The complete solution will require a combination of drugs (rapamycin, senolytics, metformin), lifestyle (diet, activity, sleep), and perhaps in the future, cellular therapies.

Nevertheless, this trial marks a transition from promises to systematic testing in humans. After years of promises in the anti-aging field, evidence-based answers are finally starting to arrive. If rapamycin truly slows aging in humans, we will know. If not, we will know that too. And that alone will be a huge achievement for science.

References:
UT Health San Antonio - Rapamycin Clinical Trial Announcement
NIA Interventions Testing Program - Rapamycin in Mice